could initiate any legal proceedings for and on behalf of Ritemed in the name of Optival and could defend or initiate any legal
proceedings in relation to its rights and liabilities as Ritemed could have if this Scheme of Amalgamation had not been made.

KMPL

Share purchase agreement dated September 25, 2019 entered into amongst KMPL, Krish Ramesh, Krishnan Sundar, Sanjay
Kumar (together “Sellers”) and our Company, read with the Investment cum Shareholders’ Agreement dated September 25,
2019

Pursuant to the share purchase agreement dated September 25, 2019, our Company purchased 86,636 equity shares of KMPL
from the Sellers for an aggregate consideration of %5 million. Further, pursuant to the Investment cum Shareholders’ Agreement
dated September 25, 2019, the Company subscribed to 125,000 fully paid up equity shares in KMPL, at 2100 each for an
aggregate consideration of 312.5 million.

MHSPPL
Business transfer agreement dated December 10, 2020 entered into amongst MHSPPL and our Company

MHSPPL and our Company entered into the BTA, pursuant to which the business undertaking of MHSPPL comprising of the
manufacturing, wholesale trading and contract manufacturing of pharmaceutical, fast-moving consumer goods and beauty
products together with, inter-alia, the employees, assets and liabilities as agreed upon between the parties, and all the business
contracts and books and records, and excluding the business of import of products and its subsequent distribution and pure
whole sale business undertaken by MHSPPL (“Business Undertaking”), was transferred to our Company as a going concern
on a slump sale basis for a lump sum purchase consideration aggregating 195.04 million on December 11, 2020 (“Effective
Date”). The purchase consideration for the Business Undertaking has been discharged by way of cash paid to MHSPPL.

Pursuant to the BTA, the Business Undertaking, along with revenues generated and all obligations and liabilities incurred by
MHSPPL between the Effective Date and the completion date, was transferred to us with effect from the Effective Date, and
our Company is the full and undisputed owner of the Business Undertaking with effect from the Effective Date.

Simultaneous with the transfer of the Business Undertaking, the employees of MHSPPL as agreed upon by the parties have
been transferred to our Company, as on the Effective Date.

The liabilities transferred to us pursuant to the BTA include provision for gratuity of all transferred employees, trade payables
relating to the domestic manufacturing and contract manufacturing business, and liabilities relating to transferred employees
and capex cost of domestic contract manufacturing and manufacturing business, and we have assumed all obligations in
connection therewith. We are liable to satisfy and discharge all transferred liabilities pertaining to or arising out of the Business
Undertaking on or after the Effective Date. MHSPPL has agreed to indemnify us from and against claims arising from
misrepresentation or fraud in or breach of warranties by MHSPPL, losses incurred due to business undertaken by MHSPPL
before the date of completion and breach or non-performance of any covenant of the BTA.

Holding Company

Our Company does not have a holding company.

Our Subsidiaries

Our Company has six direct Subsidiaries and five step-down Subsidiaries.

Details of our Subsidiaries are as follows:

Direct Subsidiaries

1. Clearancekart Private Limited (“CPL”)
Corporate Information
CPL was incorporated on March 9, 2021 as a private company limited by shares under the Companies Act, 2013. The
CIN of CPL is U52100TG2021PTC149432. The registered office of CPL is located at H. No. 11-6-56, Survey No.
257 & 258/1, Opposite IDPL Railway Siding Road, Moosapet, Kukatpally, Hyderabad 500 037.
CPL is authorized to undertake the business of trading in medical and pharmaceutical products, and carrying on the
business of online shopping, net marketing, etc. excluding banking and money circulating business. CPL does not have

any significant operations as on date.

174
